Reduction of glycosylated hemoglobin with stable insulin levels in a diabetic patient with chronic myeloid leukemia responsive to imatinib

Haematologica. 2005 Nov:90 Suppl:ECR21.

Authors

M Breccia¹, M Muscaritoli, G Alimena

Affiliation

¹ Department of Cellular Biotechnology and Hematology, University La Sapienza, Rome, Italy. breccia@bce.uniroma1.it

PMID: 16266912

No abstract available

Publication types

Case Reports

MeSH terms

Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Benzamides
Diabetes Mellitus, Type 2 / blood*
Diabetes Mellitus, Type 2 / complications
Diabetes Mellitus, Type 2 / drug therapy
Female
Glycated Hemoglobin / analysis*
Humans
Hydroxyurea / administration & dosage
Imatinib Mesylate
Insulin / blood
Insulin / therapeutic use
Interferons / administration & dosage
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / blood
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Middle Aged
Piperazines / pharmacology
Piperazines / therapeutic use*
Protein Kinase Inhibitors / pharmacology
Protein Kinase Inhibitors / therapeutic use*
Pyrimidines / pharmacology
Pyrimidines / therapeutic use*
Signal Transduction / drug effects

Substances

Antineoplastic Agents
Benzamides
Glycated Hemoglobin A
Insulin
Piperazines
Protein Kinase Inhibitors
Pyrimidines
Imatinib Mesylate
Interferons
Hydroxyurea